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Matrix metalloproteinases (MMPs) are involved in the degrada-
tion of the extracellular matrix, a central element of tumour
invasion and metastasis (Birkedal-Hansen, 1995). One of these
enzymes, MMP-2, is able to degrade type IV collagen, which is a
major component of the basement membrane (Liotta et al, 1991).
This enzyme can also modulate carcinoma cell adhesion (Ray and
Stetler-Stevenson, 1995).
MMP-2 is released in a pro-form which can be activated by
membrane-bound metalloproteinases, MT-MMP-1, -2 and -3 (Sato
et al, 1994; Kolenbrock et al, 1997; Shofuda et al, 1997) which
themselves require prior activation (Lohi et al, 1996). The active
forms of these membrane metalloproteinases cleave the 72 kDa
pro-form of MMP-2 at a specific amino acid residue generating an
active 64 kDa form (Strongin et al, 1995). The 64 kDa form of
MMP-2 can be further processed to a 62 kDa form by auto-
catalysis (Stetler-Stevenson et al, 1989a; Atkinson et al, 1995) or
the plasminogen activator (PA)/plasmin system (Baramova et al,
1997). A number of naturally occurring MMP inhibitors, TIMPs
1–4, are also found in tissues (Stetler-Stevenson et al, 1989b;
Greene et al, 1996). The activation of proMMP-2 by active
MT-MMPs is blocked by the tissue inhibitor TIMP-2 (Atkinson
et al, 1995; Strongin et al, 1995). Paradoxically TIMP-2 is also
necessary for the formation of the MT-MMP1 complex which
activates MMP-2 (Strongin et al, 1995). The tissue inhibitors
TIMPs 1–4 also block the activity of MMP-2 (Stetler-Stevenson
et al, 1989b; Greene et al, 1996).
Previous studies have identified the presence of proMMP-2 and
its active form in ovarian cancer specimens (Naylor et al, 1994;
Garzetti et al, 1995; Tamakoshi et al, 1995). One study has found
no association between the level of latent or activated MMP-2 and
the grade of ovarian carcinoma, although all of the carcinomas
investigated contained latent and active forms of MMP-2 (Naylor
et al, 1994).
MMP-2 may be involved in two different aspects of ovarian
carcinoma spread. Ovarian tumour cells could use MMP-2 to
detach from surface epithelia and migrate into the peritoneal
cavity (Niedbala et al, 1987), but they may also use MMP-2 to
invade through basement membrane into the ovarian stroma
(Campo et al, 1992; Kuwashima et al, 1995).
Fibroblasts at the invasive edge of ovarian tumours show a
striking increase in mRNA for MMP-2 and TIMP-2 (Campo et al,
1992; Autio-Harminen et al, 1993; Naylor et al, 1994). While
ovarian tumour cells in tumour tissue do not contain MMP-2 or
TIMP-2 mRNA, latent and activated MMP-2 protein can be
detected at their surface (Afzal et al, 1996). As it is possible that
tumour cell lines could utilize fibroblast MMP-2 for invasion
(Fishman et al, 1997), interactions between stromal cells and
tumour cells may play an important part in ovarian carcinoma
pathology in vivo. In this paper we report that fibroblast–
carcinoma cell interactions in vitro result in the stimulation of
proMMP-2 and TIMP-2 release by fibroblasts. We also describe a
mechanism by which collagen I can induce proMMP-2 activation
by tumour-derived, but not normal, fibroblasts.
MATERIALS AND METHODS
Materials
ProMMP-2 and antisera against MMP-2 or TIMP-2 were obtained
from TCS Biologicals (Buckingham, UK). Anti-EMMPRIN anti-
body was a kind gift from Dr Bryan P Toole, Tufts University
School of Medicine (Boston, MA, USA). The anti-b1 integrin anti-
body was from Gibco (Paisley, UK); rat tail collagen I from
Beckton-Dickinson, Bedford, MA, USA and ECL™ reagent was
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paper we show that co-culture of ovarian carcinoma cells with fibroblasts resulted in an enhanced release of proMMP-2 and TIMP-2 into the
culture medium. Cell–cell interaction was a major factor in this response and carcinoma cells stimulated proMMP-2 release from fibroblasts
but not vice versa. Collagen I, in a dose-dependent fashion, induced activation of proMMP-2 by tumour-derived, but not normal, fibroblasts.
Antibody to b1 integrin also induced proMMP-2 activation by tumour-derived fibroblasts. The activation involved the processing of proMMP-2
by a membrane-bound metalloproteinase. We propose that, in the ovarian tumour microenvironment, interaction between tumour cells and
fibroblasts may enhance fibroblast production of the proMMP-2 and TIMP-2. Collagen I, also present in the ovarian tumours, then induces
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Correspondence to: FR Balkwillobtained from Amersham (Buckinghamshire, UK). The mono-
clonal antibodies against MMP-2, MT-MMP-1 or TIMP-2 were
purchased from Oncogene Research Products (Cambridge, MA,
USA). BB2116 is a synthetic hydroxamate MMP inhibitor which
was obtained from British Biotech Pharmaceuticals (Oxford, UK).
It was dissolved in dimethyl suphoxide as a 100 mM solution and
diluted in phosphate-buffered saline (PBS) to a concentration of
30 mM. The cDNA synthesis ‘Ready to Go Kit’ was purchased
from Pharmacia, (Madison, WI, USA). The PEO1 and PEO14
cells were kindly provided by Dr S Langdon (ICRF, Edinburgh
Medical Oncology Unit, UK). SKOV3 cells were obtained from
American Type Culture Collection (Rockville, MD, USA).
The human dermal fibroblasts were a gift from Simon Broad
(ICRF, London, UK) and the human foreskin fibroblasts were
provided by Central Cell Services (ICRF, London, UK). Ovarian
tumour-derived fibroblasts were obtained by culture of tumour
tissue explants (Noel et al, 1992) and were characterized using
collagen I as a positive marker. The polymerase chain reaction
(PCR) primers were MT-MMP-1: fCACTGCCTACGAG-
AGGAAGG, rTGAATGACCCTCTGGGAGAC; MT-MMP-2:
fCGTGTCCTGCTTTACTGCAA, rCTCCAACTGGGCAAA-
GAGAG; MT-MMP-3: fCAGGGTGATGGATGGATGGATACC,
rCCTTGAGGATGGATCTTGGA; MT-MMP-4: fACGAGGT-
CTGCTCATGCA, rCAGGGAGAGGTCATGTTGGT. Other
reagents used were supplied by Sigma Chemicals Co (Poole, UK).
Methods
Cell culture and experiments
PEO1 and PEO14 cells were cultured in RPMI-1640 and 10%
fetal calf serum. SKOV3 cells and fibroblasts were cultured in
Dulbecco’s modified Eagle medium (DMEM) and 10% fetal calf
serum. The human dermal and foreskin fibroblasts were used
between passages 5 and 10. In co-culture experiments, a mixture
of 2.5 ´ 104 fibroblasts and 12.5 ´ 104 carcinoma cells was plated
in 24-well plates (1.88 cm2 per well) overnight at 37°C and 5%
carbon dioxide. Cells were washed four times with 1 ml of serum-
free medium and then incubated with 0.5 ml of medium +/– agents
for 48 h at 37°C. The medium was then removed and frozen at
–20°C. In some experiments, cells were fixed by incubation for
5 min with ice cold 80% methanol. Fixed cells were washed three
times with medium before fibroblasts or carcinoma cells were
added.
Quantitative gelatin zymography
The methods used here are described in Leber and Balkwill
(1997). Briefly, medium was treated with sample buffer and
loaded onto sodium dodecyl sulphate (SDS)-polyacrylamide gels
containing 0.12% gelatin. After electrophoresis the gel was incu-
bated in 2.5% Triton X-100 for 1 h, low-salt collagenase buffer for
18 h at 37°C and then simultaneously stained and de-stained. The
resulting gel was scanned using the Adobe Photoshop 4.0 software
package. The NIH 1.58 software package was used to quantitate
changes in gelatin concentration. The gelatinolytic activity of
unknown samples was calibrated relative to a fixed amount of
standard proMMP-2.
Triton X-114 extraction of proteins
Hydrophobic proteins were separated from aqueous proteins by
Triton X-114 at 37°C (Bordier, 1981). A total of 2 ´ 106 fibroblasts
per 25 cm2 well were washed four times in ice cold serum-free
medium and 1 ml of ice cold 1.5% Triton X-114 TBS (50 mM Tris-
HCl, pH 7.4, 150 mM sodium chloride, 2 mM Mg2+, 5 mM Ca2+)
was added for 1 h at 4°C. Cells were scraped using a rubber
policeman and the detergent mixture was spun at 13 000 g.
The supernatant was incubated at 37°C for 5 min and centrifuged
13 000 g for 2 min. The lower detergent phase, containing
hydrophobic protein, was separated from the upper aqueous phase,
containing hydrophilic proteins. The detergent phase was
subjected to three more extractions. The aqueous and detergent
phases were analysed for gelatinase activity as described (Lewalle
et al, 1995).
ProMMP-2 processing by Triton X-114 membrane protein
extracts
In order to detect proMMP-2 processing activity by fibroblast
membranes, fibroblasts (2 ´ 106) were treated with Triton X-114
and 50 ml detergent extract was mixed with 50 ml of TBS,
containing 0.02% sodium azide and proMMP-2 (10 ng).
ProMMP-2 was also incubated with detergent alone as a control.
The reaction mixture was incubated for 48 h at 37°C and the
aqueous phase was analysed by gelatin zymography (Lewalle
et al, 1995).
Western blotting
Protein in supernatant from the co-culture experiments was pre-
cipitated with acetone, run on an SDS-polyacrylamide gel and
blotted onto a nitrocellulose membrane. The membrane was
blocked by 5% milk powder and incubated with specific anti-
TIMP-2 or anti-MMP-2 antisera. The blot was treated with
HRP-linked mouse or rabbit IgG and analysed using the ECL™
system. In some cases, 0.5 ´ 106 carcinoma cells or fibroblasts
were washed and treated with 1.0 ml of 2.5% v/v Triton X-114 for
1 h at 4°C. The protein was extracted from the detergent using
chloroform–methanol (Bordier, 1981) and analysed as described
above.
Reverse transcription (RT)-PCR
RNA was extracted from cells using the TRI™-reagent, digested
by DNAse and converted to cDNA using a Pharmacia ‘Ready To
Go Kit’. cDNA was amplified using specific sets of primers and
conditions (Liabakk et al, 1996).
RESULTS
MMP-2 and TIMP-2 release
Studies of ovarian carcinoma tissue have shown that it consists of
nests of tumour cells surrounded by a stroma of fibroblast-like
cells (Naylor et al, 1994). Co-culture of dermal fibroblasts and
ovarian carcinoma cell lines resulted in similar structures to those
seen in vivo with small islands of tumour cells surrounded by
sheets of fibroblasts (Figure 1).
We used dermal fibroblasts to determine if co-culture of normal
fibroblasts with tumour cells could enhance proMMP-2 release into
the culture medium. When cultured alone, dermal fibroblasts
released proMMP-2 as measured by zymography (Figure 2A).
Ovarian carcinoma cell lines also released small amounts of
proMMP-2 which varied with cell line (Figure 2A). In co-culture
experiments with dermal fibroblasts and the ovarian tumour cell lines
PEO1, PEO14 or SKOV3, a ratio of 1:5 was chosen because at the
leading edge of tumour tissue there is an excess of tumour cells to
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of proMMP-2 was found in such co-cultures (Figure 2A). This
enhancement of proMMP-2 release during co-culture was quantified
and found to be significant, P < 0.001 (Figure 2B).
We then isolated fibroblasts from ovarian tumours and co-cultured
them with tumour cells to determine if the tumour fibroblasts
behaved in a similar way to normal fibroblasts in co-culture. Co-
culture of ovarian carcinoma cell lines with three different batches of
fibroblasts derived from ovarian carcinomas resulted in similar struc-
tures to those described in Figure 1 and also resulted in a significant
stimulation of proMMP-2 release, P < 0.05 (Figure 2C). The higher
basal release of proMMP-2 from tumour fibroblasts resulted in a
lower fold increase of proMMP-2 release compared to that found in
dermal fibroblast co-cultures (Figure 2B, C).
Western blotting of protein from cultured supernatants with
MMP-2 antisera confirmed the results seen with gelatin zymog-
raphy (Figure 3); co-culture of dermal fibroblasts and the ovarian
carcinoma cell lines enhanced the release of proMMP-2 into the
culture media (two- to sixfold increase in three independent
experiments). The level of TIMP-2 immunoreactivity in culture
medium from co-cultures was also stimulated by a similar degree
(Figure 3).
Conditioned medium from the carcinoma cell lines PEO1, PEO14
and SKOV3 did not enhance the release of proMMP-2 from dermal
fibroblasts and also had no effect on fibroblast proliferation (data not
shown). However, culture of dermal fibroblasts and fixed carcinoma
cells resulted in an significant increase in proMMP-2 release from
dermal fibroblasts, P < 0.01 (Figure 4). Culture of tumour fibrob-
lasts and fixed carcinoma cells also stimulated proMMP-2 release,
but fixed fibroblast cell membranes did not enhance proMMP-2
release from the carcinoma cells (data not shown).
ProMMP-2 activation
Co-culture of fibroblasts and ovarian carcinoma cell lines did not
result in significant activation of proMMP-2 (Figures 2A and 3).
A trace amount of the activated 62 kDa form of MMP-2 could be
detected in the medium from co-cultures, but it was < 1% of total
MMP-2 activity. However, the activated form of MMP-2 is readily
detected in ovarian carcinoma tissue (Naylor et al, 1994; Noel
et al, 1994; Ito et al, 1995). We therefore investigated the expres-
sion of MT-MMP-type enzymes in fibroblast and carcinoma cells,
and the ability of cell membranes to activate proMMP-2.
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Figure 1 Phase contrast microscopy of a co-culture of PEO1 cells and
dermal fibroblasts. A total of 2.5 ´ 104 fibroblasts and 12.5 ´ 104 PEO1 cells
were mixed and plated overnight in medium + serum. The cells were then
washed three times and incubated for 48 h in serum-free medium. T = PEO1
cells, F = dermal fibroblasts
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Figure 2 Effect of co-culture of ovarian carcinoma cell lines PEO1, PEO14
and SKOV-3 with dermal or tumour fibroblasts on the release of MMP-2 into
the culture medium. (A) Fibroblasts, carcinoma cells and carcinoma and
fibroblast cells were incubated overnight in culture medium + serum. Cells
were then washed and incubated for 48 h in serum-free medium. The
resulting conditioned medium was analysed by gelatin zymography.
ProMMP-2 standard (1), proMMP-2 and 62-kDa MMP-2 standards (2),
conditioned medium from fibroblasts (3), PEO1 (4), PEO14 (5), SKOV-3 (6),
fibroblasts + PEO1 (7), fibroblasts + PEO14 (8) and fibroblasts + SKOV-3
(9). These results are representative of three separate experiments.
(B) Culture medium from dermal fibroblasts (HDF), fibroblasts + PEO1,
fibroblasts + PEO14, and fibroblasts + SKOV-3, were analysed by
quantitative gelatin zymography. The proMMP-2 release from the carcinoma
cell lines alone was subtracted from the co-culture values. The results are
means ± s.d. from four independent experiments (* represents P < 0.001).
(C) Culture medium from three different batches of ovarian tumour
fibroblasts (OF) with the carcinoma cell line PEO1 was analysed by
quantitative zymography. The MMP-2 release from PEO1 cells alone was
subtracted from the co-culture value. The results are means ± s.d. for two
independent experiments. * represents P < 0.05 and **P < 0.01Membrane-bound metalloproteinase activators of
proMMP-2
Using RT-PCR we found that fibroblasts (both dermal and
tumour), PEO14, SKOV3, but not PEO1, ovarian cells all
expressed MT-MMP-1 mRNA. RT-PCR analysis of MT-MMP-1,
-2, -3, and -4 revealed no qualitative difference in the expression
profile for the dermal and tumour fibroblasts. The fibroblasts,
PEO14 and SKOV3 cells also had a low level of MT-MMP-1
protein in their membranes. To elevate the level of membrane
MT-MMP-1 (both the 63 and the activated 60 kDa forms) we
treated tumour fibroblasts with 50 mg ml–1 concanavalin A (Lohi
et al, 1996). However, this did not result in the activation of extra-
cellular proMMP-2 by the tumour fibroblasts (Figure 5A).
Incubation of proMMP-2 with a membrane protein extract of
tumour fibroblasts (detergent phase from Triton X-114-treated
tumour fibroblasts) converted the 72 kDa proMMP-2 to the
64 kDa form of MMP-2. This activation of MMP-2 was blocked
by an inhibitor of matrix metalloproteinases, BB2116 (30 mM),
suggesting that a MMP-type enzyme was involved in proMMP-2
processing (Figure 5B). As the tumour fibroblasts released TIMP-
2 as well as proMMP-2 (data not shown), we incubated MMP-2
complexed with TIMP-2 with the detergent phase from Triton
X-114-extracted tumour fibroblasts. No activation of proMMP-2
was seen under these conditions (Figure 5B). The detergent phase
from Triton X-114-extracted PEO14 and SKOV3, but not PEO1,
cells was also able to activate proMMP-2 and this activation of
MMP-2 was blocked by 30 mM BB2116 (data not shown).
Taken together, these results suggest that MT-MMP-type
enzymes in the membrane of both tumour cells and fibroblasts can
activate proMMP-2, but in co-culture their action is blocked, most
likely by TIMP-2. We therefore investigated factors in the extra-
cellular environment of tumours which could stimulate proMMP-
2 activation and account for the presence of active MMP-2 in
ovarian cancer biopsies. One potential candidate was collagen I,
which is a major component of ovarian carcinoma tissue (Zhu
et al, 1994). Previous studies showed that culture of normal fibro-
blasts in collagen gels results in proMMP-2 activation (Azzam and
Thompson, 1992; Seltzer et al, 1994; Gilles et al, 1997).
Collagen I treatment of fibroblasts
Treatment of normal dermal fibroblasts with soluble collagen I
(100 mgm l –1) did not increase activation of proMMP-2
(Figure 6A). However, incubation of three different batches of
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Figure 3 Effect of co-culture of the carcinoma cell lines PEO1, PEO14 and
SKOV-3 with dermal fibroblasts on the release of MMP-2 and TIMP-2 into the
culture media. The culture medium was concentrated, run on an 11% SDS-
polyacrylamide gel, then blotted. MMP-2 and TIMP-2 were detected by
specific antisera. Conditioned medium from dermal fibroblasts (1), PEO1 (2),
PEO14 (3), SKOV-3 (4), fibroblasts + PEO1 (5), fibroblasts + PEO14 (6) and
fibroblasts + SKOV-3 (7). The blots are representative of three independent
experiments
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Figure 4 Effect of methanol-fixed carcinoma cell lines on the release of
proMMP-2 from fibroblasts. PEO1, PEO14 and SKOV-3 (12.5 ´ 104 cells)
cells were incubated overnight in culture medium + serum. The carcinoma
cells were fixed by incubation in ice cold methanol for 5 min, dermal
fibroblasts (2.5 ´ 104 cells) were added and cultured overnight in culture
medium + serum. After 24 h, the cells were washed and incubated in serum
free medium for 48 h. The medium was then analysed by quantitative gelatin
zymography. The results are means ± s.d. for three independent experiments
done in duplicate. * represents P < 0.01
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Figure 5 (A) Effect of concanavalin A on MT-MMP-1 protein in membranes
from ovarian tumour fibroblasts and the activation of proMMP-2. Ovarian
fibroblast batches 1, 2 and 3 were treated with (+) or without (–) concanavalin
A (50 mg ml–1) for 24 h. The fibroblast membranes were extracted with 1.5%
Triton X-114, the proteins in the detergent phase run on an SDS-
polyacrylamide gel, blotted and MT-MMP-1 detected using specific
antiserum. The culture medium from concanavalin A-treated cells was
analysed by quantitative gelatin zymography. This experiment is
representative of three performed. (B) Activation of proMMP-2 by Triton
X-114 membrane protein extract of tumour fibroblasts. All incubations were
for 48 h at 37°C. ProMMP-2 with Triton X-114 (1), membrane protein extract
with proMMP-2 (2), membrane protein extract with proMMP-2 and BB2116
(30 mM) (3), membrane protein extract plus proMMP-2 complexed with
TIMP-2 (4). This experiment is representative of three performedtumour fibroblasts with collagen I (100 mg ml–1) resulted in the
appearance of the fully activated 62 kDa form of MMP-2 in the
cell culture medium (Figure 6A shows a typical result). A faint
gelatinolytic band of 64 kDa could also be detected between the 72
and 62 kDa forms of MMP-2 (Figure 6A). BB-2116 (30 mM)
blocked the activation of proMMP-2 by tumour fibroblasts in the
presence of collagen I (Figure 6A).
The amount of 62 kDa MMP-2 detected in the culture medium
of collagen I-treated cells was increased by 10 ± 2-fold in three
experiments. This activated form of MMP-2 could also be detected
by Western blotting with specific MMP-2 antiserum (data not
shown). The effects of collagen I (4–100 mg ml–1) on proMMP-2
activation were dose-dependent (Figure 6B). The response of
tumour fibroblasts to collagen I was only present for the first few
passages after isolation (data not shown).
The association of active MMP-2 with cell membranes
We next looked for the presence of active MMP-2 in the
membranes of collagen I and concanavalin A-treated tumour
fibroblasts. Tumour fibroblasts were incubated with medium
alone, collagen I or concanavalin A. Fibroblasts were treated with
Triton X-114 and the detergent phase (containing membrane
proteins) was analysed for gelatinase activity. The detergent phase
from fibroblasts treated with medium alone contained no gelati-
nase activity. However, the detergent phase from collagen I-treated
cells contained a 62 kDa band, whereas the detergent phase from
concanavalin A-treated cells contained only a 72 kDa gelatinase
band (Figure 7).
Integrin-mediated activation of MMP-2
Collagen I can interact with integrin collagen receptors such as
a2b1 and a1b1. Treatment of tumour fibroblasts with specific anti-
b1 integrin antibody (10 mg ml–1) also resulted in the activation of
proMMP-2 but only the 64 kDa form of MMP-2 could be
detected; BB-2116 (30 mM) blocked proMMP-2 activation by both
collagen 1 and anti-b1 integrin antibody (Figure 8). Treatment of
normal dermal fibroblasts with the anti-b1 integrin did not result in
proMMP-2 activation (Figure 8).
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Figure 6 (A) Zymogram of medium from either dermal (HDF) or ovarian carcinoma-derived fibroblasts (OF) treated with collagen I or BB2116. Cells were
treated with serum-free medium (1), plus 100 mg collagen I per ml (2), or 100 mg collagen I per ml and 30 mM BB2116 (3) for 24 h at 37°C. The experiment is
typical of three performed. (B) Zymogram of medium from ovarian-derived fibroblasts treated with different amounts of collagen I. (C) Effect of different collagen
I concentrations on the induction of proMMP-2 activation in ovarian tumour fibroblasts. Cells were treated with 100, 20, 4 and 1 mg ml–1 of collagen I for 24 h.
The results are means ± s.d. for two independent experiments done in duplicate
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Figure 7 Detection of gelatinase activity in the Triton X-114 detergent
phase from fibroblasts treated with collagen I or concanavalin A. Ovarian
fibroblasts were treated with serum-free medium (1), 100 mg collagen I per ml
(2) or 50 mg ml–1 concanavalin A (3). After incubation with 1.5% Triton X-114
for 1 h at 4°C the detergent phase was treated with gelatin-coated agarose
beads. MMPs attached to the beads were removed by sample buffer and
analysed by quantitative gelatin zymography. The experiment is typical of
three performed
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Figure 8 Effect of anti-b1 integrin antibody on proMMP-2 activation by
tumour-derived fibroblasts. (A) Ovarian fibroblasts were treated with
serum-free medium (1) anti-b1 integrin antibody (2) or anti-b1 integrin
antibody + BB2116 (3). (B) Ovarian fibroblasts were treated with serum-free
medium (1) anti-b1 integrin antibody (2) or anti-b1 integrin antibody + BB2116
(3). The culture medium was analysed by quantitative gelatin zymography.
The experiment is typical of three completed experimentsDISCUSSION
In this study, an in vitro co-culture system was used to investigate
the mechanisms by which ovarian carcinoma cells stimulate
MMP-2 release and activation by fibroblasts. Culture of ovarian
carcinoma cells with normal dermal fibroblasts or ovarian tumour
fibroblasts resulted in a stimulation of proMMP-2 release into the
medium. The stimulation of proMMP-2 release, seen when tumour
fibroblasts were cultured with ovarian cancer cells, was lower than
that seen with dermal fibroblasts, probably because of higher basal
release of proMMP-2 from tumour fibroblasts.
In co-cultures of normal fibroblasts and carcinoma cell lines,
TIMP-2 release was also enhanced. The stimulation of proMMP-2
and TIMP-2 release from co-cultures may suggest that the release
of these proteins is co-ordinately regulated. This observation is
also consistent with the lack of proMMP-2 activation found in
co-cultures since TIMP-2 inhibits MT-MMP-1 mediated MMP-2
activation.
Cultured ovarian carcinoma cells or cell lines release both
MMP-2 and TIMP-2 (Moser et al, 1994). On the basis of in vitro
studies it has been proposed that ovarian carcinoma cells may
produce MMP-2 in vivo (Fishman et al, 1997; Westerlund et al,
1997). However, in ovarian cancer biopsies, MMP-2 and TIMP-2
mRNAs localize to the stroma. Epithelial carcinoma cell produc-
tion of these molecules was not detected (Naylor et al, 1994).
This suggests that production of proMMP-2 and TIMP-2 by
cultured carcinoma cells may be an adaptation to in vitro culture
conditions.
Culture of fibroblasts with fixed carcinoma cells indicates that
cell–cell contact plays an important part in the enhancement of
proMMP-2 release seen in co-cultures. This is in agreement with
the in vivo data where only the fibroblasts close to, or in contact
with, carcinoma cells have elevated mRNA for MMP-2 and
TIMP-2 (Naylor et al, 1994). The nature of the membrane factor(s)
that stimulates proMMP-2 and TIMP-2 release is unknown.
EMMPRIN has been proposed as a regulator of MMP-2 release
from fibroblasts (Kataoka et al, 1993) and, although this protein
could be detected in PEO1 and PEO14 membranes, it could not be
detected in SKOV3 cell membranes, yet all three stimulated
proMMP-2 release (data not shown).
Both tumour fibroblasts and carcinoma cells express MT-MMP-
1 protein (Fishman et al, 1997) and we confirmed this in our study.
MT-MMP-1 mRNA is expressed in stromal fibroblast-like cells
close to tumour cells in tumour tissue (Okada et al, 1995; Ohtani
et al, 1996; Ueno et al, 1997). It has been proposed that MT-MMP-
1 is responsible for the activation of proMMP-2 in ovarian carci-
noma tissue (Fishman et al, 1997). However, co-culture of ovarian
carcinoma cells and normal or tumour fibroblasts did not result in
the activation of MMP-2, probably because extracellular TIMP-2
blocked proMMP-2 activation. Even when the amount of
MT-MMP-1 in tumour fibroblasts was increased by concanavalin
A treatment, no significant activation of MMP-2 could be seen, in
agreement with a recent study on primary human fibroblasts (Lohi
et al, 1996). Hence the expression of MT-MMP-1 protein does not
always correlate with MMP-2 activation. The ovarian carcinoma
microenvironment is rich in TIMPs (Naylor et al, 1994;
Tamamkoshi et al, 1995; Kikkawa et al, 1997) and these inhibitors
might be predicted to block the activity of MT-MMP-type enzymes.
We have found that levels of collagen I as low as 4 mg ml–1 can
stimulate the activation of proMMP-2 by tumour fibroblasts, even
in the presence of TIMPs. Normal fibroblasts did not display this
responsiveness to similar doses of collagen I. Incubation of normal
fibroblasts or invasive breast cancer cells in collagen I gels
(containing 0.5–1 mg ml–1 of collagen I), results in gross morpho-
logical changes and the intracellular activation of proMMP-2 by a
metalloproteinase-like enzyme, but no change in TIMP-2 release
(Seltzer et al, 1994; Gilles et al, 1997; Lee et al, 1997). Gilles et al
(1997) also reported that three dimensional collagen gel culture
up-regulated MT-MMP-1. However, at the lower collagen concen-
trations used in our study, the tumour-derived fibroblasts seem to
exhibit an enhanced responsiveness to collagen.
It is likely that collagen I is acting through the a2b1 or a1b1
receptors on the tumour-derived fibroblasts to stimulate proMMP-
2 activation to the 62 kDa form of MMP-2. Anti-b1 integrin anti-
body induced tumour, but not normal, fibroblasts to activate
proMMP-2 into the 64 kDa form of MMP-2. This result suggests
that the b1 integrin subunit is involved in the differential response
of tumour fibroblasts to collagen I; this could occur by an up-regu-
lation of the b1 subunit and/or integrins or an enhanced affinity of
b1 integrin for collagen I. It is of interest that treatment of rhabdo-
myosarcoma cells with anti-a3 and anti-a2 integrin antibodies
increased their ability to activate MMP-2, and also increased
proMMP-2 secretion and invasiveness through matrigel (Kubota
et al, 1997).
There are at least three possible mechanisms by which collagen
1 treatment leads to proMMP-2 activation: collagen I could
induce the expression of a metalloproteinase or metalloproteinase
activator, it may reduce TIMP-2 levels, or it may relocalize
MT-MMP-1 to specific cellular sites. At the site of invasion,
b1 integrin may possibly interact with MT-MMP-1. We also have
preliminary data that collagen 1 does not up-regulate metallo-
protease activity in tumour fibroblasts, again favouring the third
hypothesis.
In conclusion, we have found that fibroblast–carcinoma cell
interaction in vitro results in the stimulation of proMMP-2 and
TIMP-2 release by fibroblasts. This corresponds to our in vivo
observations of MMP-2 and TIMP-2 mRNA expression and local-
ization (Naylor et al, 1994). We have also found that ovarian
tumour-derived fibroblasts have a novel responsiveness to
collagen I with respect to proMMP-2 activation. Collagen I stimu-
lation of proMMP-2 activation by tumour-derived fibroblasts
appears to involve the ligation of the b1 integrin and provides a
mechanism by which ovarian tumours could activate MMP-2,
despite the presence of TIMPs. The binding of this activated
MMP-2 by receptors in the invadopodia of invasive cells, provides
a temporal window of opportunity for the utilization of active
MMP-2 in cell migration and invasion.
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